Coronary heart disease (CHD) remains the leading cause of death in the United States, yet the tools doctors have long relied on to detect it early are proving less reliable than many patients assume. Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is bringing molecular precision to a blind spot in CHD detection with clinical tests rooted in epigenetics and genetics, examining how genes are expressed and regulated at the molecular level.
According to the company, approximately 50% of individuals with coronary heart disease do not present with traditional risk factors, and conventional risk calculators have an average sensitivity of 39%. In practical terms, this means that many who “look healthy” go on to have CHD and preventable cardiac events such as a heart attack.
For decades, cardiovascular risk assessment has centered on a checklist of factors including cholesterol levels, blood pressure, smoking history, diabetes status, family history, and weight. While these factors matter and are useful pieces of the puzzle, they were never designed to capture the full biological picture of how heart disease develops. What makes CHD numbers particularly troubling is that so much of this is preventable.
Cardio Diagnostics has developed tests that delve into the molecular underpinnings of heart disease, potentially identifying individuals at risk who would otherwise be missed by standard screening. This approach could transform how clinicians assess risk and intervene early, reducing the burden of heart disease on patients and the healthcare system.
The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.
